In this Deep Dive session, Drs Kingsley Lohlun and Karen Shires present on the importance and challenges of minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) patients. Topics covered include discussion the different molecular markers, the need for standardisation among labs, the interpretation of results, and the potential implications for patient management.
Haem Deep Dive
September 9, 2024
